The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
27-Mar-18
$13.0 billion
Target:
Novartis AG’s 36.5% stake in Consumer Health Joint Venture
Acquiror:
GlaxoSmithKline plc
Advised and acted as sponsor to GlaxoSmithKline plc, the UK’s leading pharmaceutical company, on the buyout of Novartis’ 36.5% stake in their Consumer Health Joint Venture
22-Dec-17
$5.3 billion
Target:
Ladbrokes Coral Group PLC
Acquiror:
GVC Holdings PLC
Advised Ladbrokes Coral Group PLC, a leading multi-channel sports betting and gaming company, on a recommended offer from GVC Holdings PLC, a multi-national online sports betting and gaming company
31-Oct-17
$2.0 billion
Target:
Hirslanden Private Hospital Group
Advised Hirslanden Private Hospital Group, Switzerland's largest private hospital group and a wholly-owned subsidiary of Mediclinic International Plc, on the refinancing of its CHF 2.0 billion senior secured bank debt
26-May-17
$415 million
Target:
Chromalox
Acquiror:
Spirax Sarco
Advised Chromalox, a leading provider of electrical products, systems and solutions for industrial process heating and temperature management, on its sale to Spirax Sarco, a global engineering group
11-May-17
$245 million
Target:
Equity stake in Bupa Arabia
Acquiror:
Bupa Ltd.
Advised Bupa, a leading international healthcare group, on the increase of its stake in Bupa Arabia, one of the largest health insurance providers in the Kingdom of Saudi Arabia
06-Dec-16
$1.8 billion
Target:
Host Europe Group
Acquiror:
GoDaddy
Advised GoDaddy, the largest domain name registrar worldwide and a leading web hosting provider, on its acquisition of Host Europe Group, the largest privately owned web services provider in Europe
05-Oct-16
$775 million
Target:
Assets and operations of Actavis Generics in the UK and Ireland from Teva Pharmaceutical Industries Ltd.
Acquiror:
Accord Healthcare Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on its sale of assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited) for £603m (c.$775m)
05-Oct-16
$NA
Target:
Portfolio of 14 Outlicensing generic products in the EEA from Teva Pharmaceutical Industries Ltd.
Acquiror:
Accord Healthcare Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 14 Outlicensing pharmaceutical products in the EEA to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited).
04-Oct-16
$223 million
Target:
US rights to Toprol-XL (AstraZeneca)
Acquiror:
Aralez Pharmaceuticals Inc.
Advised Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company in connection with the financing of its acquisition of the US rights to cardiovascular drug Toprol-XL (metoprolol succinate) and its Authorized Generic from AstraZeneca.
29-Sep-16
$628 million
Target:
van Gansewinkel Groep BV
Acquiror:
Shanks Group plc
Advised Shanks Group plc, a leading international waste to product business, on the proposed merger with van Gansewinkel Groep BV, one of the leading waste management service providers, recyclers and suppliers of high-quality secondary raw materials in the Benelux region.
16-May-16
$874 million
Target:
Equinix Data Center Assets
Acquiror:
Digital Realty Trust
Advised Digital Realty Trust, the world's largest wholesale colocation services and data center solutions provider, on its acquisition of a portfolio of eight carrier-neutral European data centers from Equinix
25-Apr-16
$3.4 billion
Target:
Divestment assets of Ball and Rexam
Acquiror:
Ardagh Group SA
Advised Ball Corporation on the acquisition of Rexam plc and provided a fairness opinion to the Board of Directors of Ball Corporation on the sale of select metal beverage can assets in Europe, Brazil and the United States to satisfy certain regulatory requirements in connection with its proposed acquisition of Rexam
14-Apr-16
$NA
Target:
Frieze Events Ltd. / Frieze Publishing Ltd.
Acquiror:
WME | IMG Global
Advised Frieze, the premier art events and media company, on its strategic investment and partnership with WME IMG Global
07-Apr-16
$105 million
Target:
Wireless Infrastructure Group
Acquiror:
3i Infrastructure plc
Advised 3i Infrastructure plc, a leading UK listed investor in infrastructure businesses and assets, on its acquisition of a 36% economic interest in Wireless Infrastructure Group, the UK’s 2nd largest independent telecommunications tower company
01-Dec-15
$164 million
Target:
Incotec Group BV
Acquiror:
Croda International Plc
Advised Croda International Plc, a leading UK listed global specialty chemicals producer, on its acquisition of Incotec Group BV, a Netherlands based provider of seed enhancement technologies
01-Dec-15
$NA
Target:
Allied Healthcare
Acquiror:
AURELIUS Investments
Advised Saga plc on the disposal of Allied Healthcare, the leading local authority-funded domiciliary care business in the UK, to AURELIUS Investments
02-Nov-15
$NA
Target:
Reaction Engines Limited
Acquiror:
BAE Systems plc
Advised Reaction Engines Limited, a privately-held company located in the United Kingdom, on a strategic investment by BAE Systems plc, a leading defense, security and aerospace company based in the United Kingdom, to accelerate the company’s development of a new aerospace engine class
28-Oct-15
$NA
Target:
DataLase Ltd
Acquiror:
Sato Holdings Corporation
Advised Sato Holdings Corporation, a leading global provider of Auto-ID solutions, on its acquisition of a significant minority stake in DataLase Ltd, a UK-based provider of materials for laser coding and marking of products and packaging
14-Oct-15
$330 million
Target:
Professional Service Industries, Inc.
Acquiror:
Intertek Group plc
Advised Intertek Group plc, a leading quality solutions provider to industries worldwide, on its $330 million acquisition of Professional Service Industries, Inc. (“PSI”), a leading US based provider of testing and assurance services to commercial and civil construction markets
27-Jul-15
$40.5 billion
Target:
Allergan Generics
Acquiror:
Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company, on the acquisition of Allergan plc’s Generics business
24-Jul-15
$5.6 billion
Target:
Gala Coral Limited
Acquiror:
Ladbrokes plc
Advised Ladbrokes plc, a leading UK betting and gaming company, on the recommended all-share merger with certain businesses of Gala Coral Limited, including Coral Retail, Eurobet Retail and Gala Coral Online
02-Jun-15
$NA
Target:
Portfolio of GlaxoSmithKline plc consumer and OTC brands
Acquiror:
Perrigo Company plc
Advised GlaxoSmithKline plc, a leading British pharmaceutical company, on the disposal of a portfolio of consumer and OTC brands to Omega Pharma NV, a subsidiary of Perrigo Company plc
24-Apr-15
$575 million
Target:
Scholastic Corporation’s Educational Technology and Services business
Acquiror:
Houghton Mifflin Harcourt Company
Advised Scholastic Corporation, a children’s publishing and education company, on the sale of its Educational Technology and Services business to Houghton Mifflin Harcourt Company, an educational and trade publisher
30-Mar-15
$950 million
Target:
Quindell plc’s Professional Services Division
Acquiror:
Slater and Gordon
Advised Slater and Gordon Limited, an ASX-listed international consumer law firm, on the acquisition of Quindell plc’s Professional Services Division, the UK’s leading personal injury law firm operating across the claims value chain, and associated A$890 million equity and A$375 million debt raisings
24-Feb-15
$NA
Target:
Azelis Group (majority owned by 3i)
Acquiror:
Funds advised by Apax Partners
Advised 3i on the sale of Azelis Group, a leading pan-European distributor of specialty chemicals with an emerging presence in Asia, to funds advised by Apax partners